Fate of Excess Melatonin

The Metabolic Fate of Excess Oral Melatonin in the Human Body

Melatonin, a hormone that regulates sleep-wake cycles, is frequently used in supplemental form to address sleep disorders and jet lag. With common doses ranging from 0.5mg to 5mg, understanding how the body processes excess melatonin is essential for its safe use. This article examines what happens when a 5mg dose of melatonin is ingested, highlighting the body's metabolic pathways and potential effects.

Absorption and Bioavailability

Upon oral administration, melatonin is quickly absorbed through the gastrointestinal tract. Peak plasma concentrations are typically reached within 30 to 60 minutes [1]. The bioavailability of melatonin is highly variable, influenced by factors such as individual metabolic differences and liver function, ranging from 10% to 56% [2]. This variability impacts how long melatonin remains active in the body.

Metabolism

Melatonin is extensively metabolized in the liver via the cytochrome P450 enzyme system, primarily by CYP1A2. It is converted into 6-hydroxymelatonin, which is then conjugated with sulfate to form 6-sulfatoxymelatonin, a water-soluble form that facilitates excretion [3]. This process ensures that excess melatonin is efficiently metabolized and prepared for elimination.

Excretion

The majority of a 5mg dose is excreted in the urine as 6-sulfatoxymelatonin within 24 hours. Only a small fraction of the dose is excreted unchanged [4]. This efficient excretion process helps prevent the accumulation of melatonin in the body.

Effects of a 5mg Dose

1. Daytime Drowsiness: A 5mg dose may lead to elevated plasma levels that persist into the morning, potentially causing daytime drowsiness or lethargy, especially if taken late at night [5].
2. Hormonal Interactions: High doses of melatonin can influence reproductive hormones, although the clinical significance of this interaction requires further study [6].
3. Mood and Cognitive Effects: Some individuals may experience mood changes or cognitive effects, such as mild depression or confusion, due to melatonin's interaction with neurotransmitter systems [7].
4. Individual Variability: Responses to a 5mg dose can vary significantly based on factors such as age, liver function, and concurrent medication use [8].

Recommendations

While melatonin is generally considered safe, starting with the lowest effective dose can help minimize potential side effects and allow for assessment of individual tolerance. It is advisable to consult with a healthcare provider before starting or adjusting melatonin dosage, particularly for individuals with underlying health conditions or those taking other medications.

Conclusion

A 5mg dose of oral melatonin is processed efficiently by the body through rapid absorption, metabolism, and excretion. While generally safe, such a dose may lead to increased daytime drowsiness and potential hormonal interactions. Understanding these processes can guide appropriate dosing and ensure the safe use of melatonin supplements.

References

1. Di, W. L., Kadva, A., Johnston, A., & Silman, R. (1997). Variable bioavailability of oral melatonin. New England Journal of Medicine, 336(2), 102-102.
2. DeMuro, R. L., Nafziger, A. N., Blask, D. E., Menhinick, A. M., & Bertino, J. S. Jr. (2000). The absolute bioavailability of oral melatonin. The Journal of Clinical Pharmacology, 40(7), 781-784.
3. Aldhous, M. E., Franey, C., Wright, J., & Arendt, J. (1985). Plasma concentrations of melatonin in man following oral absorption of different preparations. British Journal of Clinical Pharmacology, 19(4), 517-521.
4. Zhdanova, I. V., Wurtman, R. J., Lynch, H. J., Ives, J. R., Dollins, A. B., Morabito, C., ... & Balcioglu, A. (1995). Sleep-inducing effects of low doses of melatonin ingested in the evening. Clinical Pharmacology & Therapeutics, 57(5), 552-558.
5. Buscemi, N., Vandermeer, B., Hooton, N., Pandya, R., Tjosvold, L., Hartling, L., ... & Klassen, T. P. (2006). The efficacy and safety of exogenous melatonin for primary sleep disorders: a meta-analysis. Journal of General Internal Medicine, 21(12), 1151-1158.
6. Luboshitzky, R., & Lavie, P. (2006). Melatonin and sex hormone interrelationships—a review. Journal of Pediatric Endocrinology and Metabolism, 19(3), 513-521.
7. Anderson, G., & Maes, M. (2015). Melatonin: an overlooked factor in schizophrenia and in the inhibition of anti-psychotic side effects. Metabolic Brain Disease, 30(3), 755-759.
8. Arendt, J. (1997). Safety of melatonin in long-term use (?). Journal of Biological Rhythms, 12(6), 673-681.

Legal Disclosure: This article is for informational purposes only and is not intended to provide medical advice. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition or treatment.